 Home > Active Ingredient News > Drugs Articles > Concord Kirin CCR4 targeted preparation Poteligeo real-life research data announced

Concord Kirin CCR4 targeted preparation Poteligeo real-life research data announced

 Last Update: 2021-10-19
 Source: Internet
 Author: User

Tags

biofilm treatment protocol

cancer injection treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Concord Kirin announced a new study on real-world data, showing that patients with cutaneous T-cell lymphoma (CTCL) treated with the CCR4 targeting agent Poteligeo (mogamulizumab) have a higher response rate than Remission rates observed in previous studies

MAVORIC is a pivotal Phase 3 study, carried out in previously treated adult patients with granuloma fungoides (MF) or Sezari syndrome (SS), combining Poteligeo with the positive control drug Zolinza (vorinostat, vorinostat) ) For comparison

Concord Kylin collected and analyzed data from the medical records of 124 MF patients and SS patients from 14 specialist treatment centers in France from February 2014 to March 2020

Poteligo has also been proven to have good safety.

CTCL is a rare type of non-Hodgkin's lymphoma.

Malignant T lymphocytes in MF and SS continue to express CCR4 molecules

In China, Poteligeo's listing application was accepted by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration in July this year

Reference source:

New Real World Evidence Underlines Benefits of POTELIGEO®▼ (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Tirzepatide Lyophilized powder Vial 5mg 10mg 15mg 20mg 30mg customize 99% Purity with third side checking report

CAS No.: 2023788-19-2

Pharmacy Grade

$50-60/UNIT FOB

Wight loss Lyophilized Semaglutide Petide powder CAS 910463-68-2 with 99.9% purity

CAS No.: 910463-68-2

Pharmacy Grade

$140-175/G FOB

High Quality (E,E,E,E)-Squalene CAS NO 111-02-4 GMP ISO9001 EP Pharma grade Manufacture

CAS No.: 111-02-4

EP Pharma grade

$400-405/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.